These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 23148588)

  • 1. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Dailly E; Raffi F; Biron C; Allavena C; Jolliet P
    Fundam Clin Pharmacol; 2008 Feb; 22(1):101-4. PubMed ID: 18251726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
    Florence E; De Wit S; Castagna A; Ribera E; Hill A; Vanaken H; van Delft Y; Marks S
    Int J STD AIDS; 2010 Mar; 21(3):224-5. PubMed ID: 20071441
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
    Cattaneo D; Gervasoni C
    AIDS; 2011 Apr; 25(7):1012-3; author reply 1011-2. PubMed ID: 21412129
    [No Abstract]   [Full Text] [Related]  

  • 9. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
    Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
    Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
    Barrail-Tran A; Yazdanpanah Y; Goldwirt L; Chêne G; Colin C; Piketty C; Bollens D; Katlama C; Descamps D; Molina JM; Fagard C; Taburet AM;
    AIDS; 2010 Oct; 24(16):2581-3. PubMed ID: 20960678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
    Hull MW; Montaner JS
    Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 18. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
    Ter Heine R; Mulder JW; van Gorp EC; Wagenaar JF; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2010 May; 69(5):475-83. PubMed ID: 20573083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
    Dailly E; Raffi F; Perré P; Martin J; Deslandes G; Jolliet P
    HIV Med; 2009 Oct; 10(9):586-9. PubMed ID: 19486187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.